Inari Medical, Inc.

  • Market Cap: Small Cap
  • Industry: Medical Specialties
  • ISIN: US45332Y1091
USD
79.97
0.00 (0.00%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Inari Medical, Inc. stock-summary
stock-summary
Inari Medical, Inc.
Medical Specialties
Inari Medical, Inc. is a commercial-stage medical device company. The Company is focused on developing products to treat venous diseases. The Company’s product offering consists of two minimally-invasive, catheter-based mechanical thrombectomy devices. The Company built two products for the treatment of venous thromboembolism (VTE deep vein thrombosis) and pulmonary embolism (PE). The Company provides two products ClotTriever and FlowTriever. ClotTriever product is Food and Drug Administration (FDA) cleared for the removal of clot from peripheral blood vessels and is used to deep vein thrombosis (DVT). FlowTriever product is thrombectomy system FDA cleared for the treatment of pulmonary embolism (PE). Its product ClotTriever and FlowTriever offer clinical benefits and provides safety to limit effectiveness of thrombolytic drugs and repurposed arterial devices for the treatment of VTE.
Company Coordinates stock-summary
Company Details
9 Parker, Suite 100, Suite 100 , IRVINE CA : 92618
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 84 Schemes (62.07%)

Foreign Institutions

Held by 143 Foreign Institutions (16.91%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Donald Milder
Independent Chairman of the Board
Mr. William Hoffman
President, Chief Executive Officer, Director
Ms. Cynthia Lucchese
Independent Director
Mr. Kirk Nielsen
Independent Director
Mr. Geoff Pardo
Independent Director
Dr. Jonathan Root
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
153 Million
(Quarterly Results - Sep 2024)
Net Profit:
-18 Million
stock-summary
Industry

Medical Specialties

stock-summary
Market cap

USD 4,683 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

97.97%

stock-summary
Debt Equity

-0.25

stock-summary
Return on Equity

-11.07%

stock-summary
Price to Book

10.77